CADD-15. TRANSLATIONAL DISCOVERY OF THERAPEUTIC TARGETS FOR GLIOBLASTOMA
نویسندگان
چکیده
منابع مشابه
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
Even though glioblastoma, WHO grade IV (GBM) is one of the most devastating adult cancers, current treatment regimens have not led to any improvements in patient life expectancy or quality of life. The constitutively active EGFRvIII receptor is one of the most commonly mutated proteins in GBM and has been linked to radiation and chemotherapeutic resistance. To define the mechanisms by which thi...
متن کاملExtracellular Microenvironment Components of Glioblastoma as Possible Therapeutic Targets
Glioblastoma multiforme (GBM), is a highly invasive primary brain tumor representing more than half of all gliomas with an average patient survival time of only 12 to 15 months [1]. Unlike tumors derived from peripheral tissues, GBM is known to rarely metastasize outside its original location in the central nervous system (CNS). This characteristic is attributed to both a limited survival time ...
متن کاملCancer stem cells: therapeutic targets
Cancer stem cells (CSCs) have been identified as rare cellular populations in many cancers, including leukemia and solid tumors. This minor subpopulation of cancerous cells is immortal tumor-initiating cells which thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug/radiation resistance. Low proliferative rate, high self-renewing capacity, differentiatio...
متن کاملGlioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Glioblastoma (GBM), a WHO-defined Grade IV astrocytoma, is the most common and aggressive CNS malignancy. Despite current treatment modalities, the survival time remains dismal. The main cause of mortality in patients with this disease is reoccurrence of the malignancy, which is attributed to treatment-resistant cancer stem cells within and surrounding the primary tumor. Inclusion of novel ther...
متن کاملTherapeutic Discovery A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets
The therapeutic use of antibodies is restricted by the limited access of antibodies to intracellular compartments. To overcome this limitation, we developed a cell-penetrating monoclonal antibody, mAb 3E10, as an intracellular delivery vehicle for the intracellular and intranuclear delivery of antibodies constructed as bispecific single-chain Fv fragments. Because MDM2 is an important target in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2018
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noy148.1160